Use of levo-ornidazole in the preparation of anti-anaerobic bacteria infection drugs
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 10, 2013
Grant Date -
Dec 31, 2009
app pub date -
Apr 17, 2006
filing date -
Apr 28, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully